We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Wearable Device Monitors Vital Signs Continuously

By HospiMedica International staff writers
Posted on 27 Oct 2015
Print article
Image: The Zensor system (Photo courtesy of Intelesens).
Image: The Zensor system (Photo courtesy of Intelesens).
A novel wearable vital signs monitor facilitates real time monitoring of electrocardiogram (ECG) signals, heart rate, respiration rate, and motion.

The Zensor is a miniaturized clip on device that is attached to a disposable adhesive electrode array that monitors a range of vital signs data, transmitting information wirelessly to a remote server for a period of up to 168 hours (7 days) in a home or remote setting. During the week long monitoring session, the device is also capable of recording full interpretive ECG data for download and analysis by a trained healthcare professional. The system provides full configurability of the duration and frequency of monitored data, including the length of each recorded event.

Features of the system include 3-lead ECG full disclosure and cardiac event monitoring; symptomatic and asymptomatic arrhythmia event detection using on-device algorithms; monitoring of heart rate, respiration, and motion; and a rechargeable battery, replaceable in situ, when needed for extended periods of continuous use. The highly miniaturized, reusable, compact and lightweight body-worn wireless sensor is non-irritant, and is easy-to-apply using the long-life patch electrodes.

Transmission of detected arrhythmias and rate limit breaches is over standard Wi-Fi or mobile hotspot to the zensoronline website, with normal ranges and pre and post event data reporting configurable by the clinician. Data can also be downloaded via USB to zensor+ software. The Zensor vital signs monitor is a product of Intelesens (Belfast, United Kingdom), and has been approved by the US Food and Drug Administration (FDA).

“FDA clearance gives Intelesens and customers confidence in Zensor’s quality, robustness, and clinical efficacy,” said Stephen Henderson, commercial manager of Intelesens. “It brings a step closer the promise of preventative, predictive and protective technology, enabling clinicians proactively to help safeguard the quality of the life patients have yet to live.”

Related Links:

Intelesens
Zensoronline


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Critical Care Trolley
CCT-PX

Print article

Channels

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.